Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 … [Read More...] about Vivani Medical initiates first-in-human GLP-1-eluting implant study
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Abbott, Dexcom settle global CGM patent litigation
Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies' continuous glucose monitor (CGM) technologies. … [Read More...] about Abbott, Dexcom settle global CGM patent litigation
The 5 most-read Drug Delivery Business News stories of 2024
There has been no shortage of news across the diabetes and drug delivery markets over the course of 2024. At Drug Delivery Business News, we've tried to cover it all. From product launches to major regulatory nods — with significant partnerships … [Read More...] about The 5 most-read Drug Delivery Business News stories of 2024
BD hit with FDA warning related to Pyxis medication management
The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of its $12 billion CareFusion acquisition in 2015. The warning letter, dated Nov. 22 and posted on Dec. 17, involves … [Read More...] about BD hit with FDA warning related to Pyxis medication management
Oura raises $200M from investors including Dexcom
Oura announced today that it completed a $200 million Series D funding round that included Dexcom (Nasdaq:DXCM). The investment comes as part of a new health monitoring partnership between the continuous glucose monitor (CGM) maker and Oura, the … [Read More...] about Oura raises $200M from investors including Dexcom
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 … [Read More...] about Vivani Medical initiates first-in-human GLP-1-eluting implant study
Dexcom launches generative AI platform for glucose biosensing
Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its glucose biosensing technology. San Diego-based Dexcom says this makes it the first continuous glucose monitor (CGM) manufacturer to … [Read More...] about Dexcom launches generative AI platform for glucose biosensing
BD to pay SEC $175M to settle Alaris investigation
BD (NYSE:BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system. The investigation relates to prior public disclosures and SEC reporting regarding Alaris, an infusion pump system. BD … [Read More...] about BD to pay SEC $175M to settle Alaris investigation
MannKind reports positive data for inhaled insulin for children
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children. INHALE-1 looked at Afrezza in children and adolescents between 4-17 years of age. The company expects the data to support … [Read More...] about MannKind reports positive data for inhaled insulin for children
European court rules in favor of Abbott in Dexcom CGM patent spat
The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom (Nasdaq:DXCM). Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading … [Read More...] about European court rules in favor of Abbott in Dexcom CGM patent spat
Tandem makes t:slim X2 insulin pump available with Dexcom G7 in Canada
Tandem Diabetes Care (Nasdaq:TNDM) announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with Dexcom (Nasdaq:DXCM) CGMs. Following authorization from Health Canada, in-warranty pump users can access full … [Read More...] about Tandem makes t:slim X2 insulin pump available with Dexcom G7 in Canada
In case you missed it
- Senseonics highlights early success with Eversense 365 launch
- Insulet prevails in IP battle with patch pump maker EOFlow
- Embecta to lay off 118 in Massachusetts following patch pump program discontinuation
- Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
- Modular Medical brings in $8.2M
- Embecta discontinues insulin patch pump program, plans restructuring
- Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
- Medtronic wins FDA nod for new InPen app to support launch with Simplera CGM
- Insulet Omnipod 5 is now compatible with Abbott FreeStyle Libre 2 Plus in the U.S.
- Dexcom invests $75M in Oura as companies strike health monitoring partnership
- Medtronic to submit MiniMed 780G to FDA for type 2 diabetes in 2025, updates on patch pump
- Abbott opens new FreeStyle Libre manufacturing plant in Ireland
- The biggest diabetes tech stories of the year so far
- What diabetes tech companies are doing on World Diabetes Day 2024
- Dexcom highlights diabetes awareness with global star power
Clinical Trials
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects. This study follows FDA approval for an investigational new drug (IND) application for […]
MannKind reports positive data for inhaled insulin for children
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children. INHALE-1 looked at Afrezza in children and adolescents between 4-17 years of age. The company expects the data to support an upcoming request for a supplemental new drug application (sNDA) meeting with the FDA. It aims to […]
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]
Abbott reports sustained benefits with Esprit drug-eluting stent
Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting resorbable scaffold system treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. The first-of-its-kind stent provides support to the vessel […]
Elixir Medical has positive data for drug-eluting bioadaptive implant
Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]
